What is the status of VX-770?
VX-770 is currently being evaluated in a Phase 3 registration program. Results from this program are expected in the first half of 2011, and Vertex anticipates it will submit a New Drug Application for VX-770 to the U.S. Food and Drug Administration (FDA) in the second half of 2011. The registration program is designed to generate data that the FDA can use to determine if VX-770 is safe, effective and acceptable for approval.